Prodotti GS / Area Kite
ZUMA-7 Study Results
Kite announces Yescarta car t-cell therapy improved event-free Survival by 60% over chemotherapy plus stem cell transplant in secondline Relapsed or refractory large b-cell lymphoma.
Read the full Press Release
Grazie per il tuo feedback!